Novo dropped its patent-infringement case against telehealth provider Hims & Hers after the companies agreed that Hims would ...

Hims & Hers has abandoned plans to sell a compounded version of Novo Nordisk’s Wegovy (semaglutide) pill, though Novo and the US Food and Drug Administration (FDA) have already set wheels in motion ...

Novo Nordisk is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe on the company's patents, and is seeking to recover damages. The move escalates the ...

Pharmaceutical giant Novo Nordisk announced Monday it is suing telemedicine platform Hims & Hers for allegedly “deceiving patients and putting their health at risk” by selling compounded versions of ...

Novo Nordisk is suing online telehealth provider Hims & Hers for mass marketing cheaper, unapproved copies of the drugmaker's new Wegovy obesity pill and injections in the U.S. Novo is asking the ...

Hims & Hers Health has agreed to stop selling compound versions of Novo Nordisk’s Wegovy and other weight-loss drugs, ending ...

Add Yahoo as a preferred source to see more of our stories on Google. Novo Nordisk files suit against telehealth provider Hims & Hers, alleging unauthorized versions of Ozempic and Wegovy. The case ...

Wegovy and Ozempic maker Novo Nordisk NOVO.B6.94%increase; green up pointing triangle filed a lawsuit against Hims & Hers as it seeks a ban on the telehealth provider offering copycat versions of the ...